- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03298412
Effect of Blinatumomab on Minimal Residual Disease (MRD) in Diffuse Large B-Cell Lymphoma (DLBCL) Subjects Post Autologous Hematopoietic Stem Cell Transplantation (aHSCT)
A Phase 2 Open-Label Study to Determine the Effect of Blinatumomab on Minimal Residual Disease in Subjects With High-risk Diffuse Large B-cell Lymphoma Post-autologous Hematopoietic Stem-cell Transplantation.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
New South Wales
-
St Leonards, New South Wales, Australia, 2065
- Research Site
-
Westmead, New South Wales, Australia, 2145
- Research Site
-
-
Victoria
-
Clayton, Victoria, Australia, 3168
- Research Site
-
Geelong, Victoria, Australia, 3220
- Research Site
-
-
-
-
-
Charleroi, Belgium, 6000
- Research Site
-
Leuven, Belgium, 3000
- Research Site
-
Liege, Belgium, 4000
- Research Site
-
-
-
-
-
Créteil Cedex, France, 94010
- Research Site
-
Lille, France, 59037
- Research Site
-
Marseille, France, 13009
- Research Site
-
Montpellier cedex 5, France, 34295
- Research Site
-
Paris Cedex 10, France, 75475
- Research Site
-
Pessac Cedex, France, 33604
- Research Site
-
Pierre Benite Cedex, France, 69495
- Research Site
-
Rouen, France, 76038
- Research Site
-
-
-
-
-
Athens, Greece, 11527
- Research Site
-
Athens, Greece, 10676
- Research Site
-
Thessaloniki, Greece, 57010
- Research Site
-
-
-
-
-
Bergamo, Italy, 24127
- Research Site
-
Brescia, Italy, 25123
- Research Site
-
Firenze, Italy, 50134
- Research Site
-
Milano, Italy, 20162
- Research Site
-
Palermo, Italy, 90146
- Research Site
-
Torino, Italy, 10126
- Research Site
-
-
-
-
-
Bellinzona, Switzerland, 6500
- Research Site
-
Bern, Switzerland, 3010
- Research Site
-
Lausanne, Switzerland, 1011
- Research Site
-
Zurich, Switzerland, 8091
- Research Site
-
-
-
-
Georgia
-
Atlanta, Georgia, United States, 30342
- Research Site
-
-
Illinois
-
Maywood, Illinois, United States, 60153
- Research Site
-
-
Ohio
-
Cleveland, Ohio, United States, 44195
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75246
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion and Exclusion Criteria - Part 1
Inclusion Criteria - Part 1
- Subject has provided informed consent prior to initiation of any study-specific activities/procedures or subject's legally acceptable representative has provided informed consent prior to any study-specific activities/procedures being initiated when the subject has any kind of condition that, in the opinion of the investigator, may compromise the ability of the subject to give written informed consent.
- Age ≥ 18 at time of informed consent
- Biopsy-proven DLBCL excluding DLBCL that represents transformation of indolent non-Hodgkin's lymphoma (NHL) Note: Lymphoblastic Lymphoma and Burkitt Lymphoma histology are not eligible
Subject has ≥ 1 characteristic feature of high-risk DLBCL:
- High-risk first complete remission (defined as interim positron emission tomography - computed tomography (PET-CT) positive or < complete remission to frontline chemotherapy AND achieved complete remission to platinum-containing salvage)
- Relapse within 1 year of diagnosis
- Secondary age-adjusted international prognostic index > 1
- Partial response/partial metabolic response after minimum of 2 cycles of platinum-containing salvage chemotherapy
- C-myc rearrangement
- aHSCT with high-dose chemotherapy following first (or later) salvage treatment.
- PET-CT negative (Deauville score ≤ 3) 90 days (± 30 days) post aHSCT
- Available relapsed and/or diagnostic pathology formalin-fixed paraffin-embedded (FFPE) tumor block or slide samples at the time of enrollment including the successful identification of malignant clone sequences by the central laboratory.
- MRD plasma sample collected ≤ 3 weeks after the post aHSCT PET-CT scan
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2.
Adequate organ function determined ≤ 3 weeks prior to enrollment defined as follows:
- Hematological:
Absolute neutrophil count (ANC) ≥ 1.0 x 109/L Platelet count ≥ 75 x 109/L Hemoglobin ≥ 8 g/dL
- Renal:
Creatinine clearance ≥ 50 mL/min Cockcroft-Gault equation
- Hepatic:
Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) < 3 x upper limit of normal (ULN) Total bilirubin < 2 x ULN (unless Gilbert's Disease or if liver involvement with lymphoma)
- Subject will be available to complete all protocol-required study visits or procedures, and/or to comply with all required study procedures to the best of the subject's and investigator's knowledge including but not limited to:
- Completion of up to a 24-month run-in period
Completion of all regularly scheduled study visits including blood draws for MRD assessment, clinical disease state assessment, PET-CT scans (ie, at time of MRD positivity or relapse), assignment to treatment with blinatumomab
- Other Inclusion criteria may apply. See "Inclusion and Exclusion criteria - Part 2".
Exclusion Criteria - Part 1
- Clinically relevant central nervous system (CNS) pathology such as epilepsy, seizure, paresis, aphasia,stroke, severe brain injury, dementia, Parkinson's disease, cerebellar disease, organic brain syndrome, and psychosis
- Evidence of CNS involvement with DLBCL at disease evaluation obtained prior to starting blinatumomab
- Current autoimmune disease or history of autoimmune disease with potential of CNS involvement
- Prior anti-CD19 directed therapies
- Prior alloHSCT
- Received radiation ≤ 2 weeks prior to enrollment
- Infection with human immunodeficiency virus or chronic infection with hepatitis B virus (hepatitis B surface antigen positive) or hepatitis C virus (anti-hepatitis C virus positive)
History of malignancy other than DLBCL within the past 3 years with the following exceptions:
- Malignancy treated with curative intent and with no known active disease present for ≥ 3 years before enrollment and felt to be at low risk for recurrence by the treating physician
- Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease
- Adequately treated cervical carcinoma in situ without evidence of disease
- Adequately treated breast ductal carcinoma in situ without evidence of disease
- Prostatic intraepithelial neoplasia without evidence of prostate cancer
- Adequately treated urothelial papillary noninvasive carcinoma or carcinoma in situ
- Subject has known hypersensitivity to immunoglobulins or any of the products or components to be administered during dosing.
- History or evidence of any other clinically significant disorder, condition or disease (with the exception of those outlined above) that, in the opinion of the investigator or Amgen physician, if consulted, would pose a risk to subject safety or interfere with the study evaluation, procedures or completion.
- Women who are pregnant or breastfeeding or planning to become pregnant or breastfeed while receiving blinatumomab and for an additional 48 hours after the last treatment dose of blinatumomab. (Females of child bearing potential should only be included after a negative highly sensitive urine or serum pregnancy test.)
- Women of childbearing potential unwilling to use an acceptable method of effective contraception while receiving blinatumomab and for an additional 48 hours after last dose of blinatumomab. Note: The pregnancy, breastfeeding and contraceptive requirements are specific to blinatumomab. The investigator is responsible for providing the subject (male and female) with pregnancy and breastfeeding (female only) avoidance requirements for other medications given during the study.
Currently receiving treatment in another investigational device or drug study or less than 30 days since ending treatment on another investigational device or drug study. Other investigational procedures while participating in this study are excluded.
- Other Exclusion criteria may apply. See "Inclusion and Exclusion criteria - Part 2".
Inclusion and Exclusion Criteria - Part 2
Inclusion Criteria - Part 2
- MRD-positive assessment (by NGS analysis) at enrollment or at any time during the run-in 1 period
- PET-CT negative (defined by Deauville criteria ≤ 3) at run-in 2 performed ≤ 3 weeks from MRD test result available to the site at run-in 1. Historical PET-CT are allowed if performed ≤ 6 weeks from day 1 (first dose of blinatumomab) and subject has no clinical signs or symptoms suggestive of disease progression (eg, increase in lactate dehydrogenase [LDH] not otherwise explained)
Adequate organ function determined ≤ 7 days prior to treatment assignment with blinatumomab as follows:
- Hematological:
ANC ≥ 1.0 x 109/L Hemoglobin ≥ 8 g/L Platelet count ≥ 75 x 109/L
- Renal:
Creatinine clearance ≥ 50 mL/min Cockcroft-Gault equation
- Hepatic:
AST and ALT < 3 x ULN Total bilirubin < 2 x ULN (unless Gilbert's Disease or if liver involvement with lymphoma)
Exclusion Criteria - Part 2
- Subject has active infection requiring systemic therapy
- Any change in the part 1 eligibility criteria during the run-in period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Blinatumomab
After a run-in period of up to 24 months to evaluate MRD status and assess eligibility for treatment assignment, participants received blinatumomab intravenous (IV) infusion at an initial dose of 9 μg/day for the first 7 days of treatment, escalated (dose-step) to 28 μg/day starting on Day 8 (Week 2), followed by a dose-step to 112 μg/day starting on Day 15 (Week 3) and continuing until completion of therapy (Day 57 of Cycle 1). Cycle 1 of blinatumomab treatment is 12 weeks (84 days) in duration and includes 8 weeks (56 days) of blinatumomab IV infusion followed by a 4-week (28-day) treatment-free interval. |
Blinatumomab is administered as a continuous IV infusion.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MRD-Negative Rate at the End of Cycle 1
Time Frame: 12 weeks (84 days)
|
The estimated MRD-negative rate, calculated as the percentage of participants with MRD-negative status after treatment with blinatumomab.
MRD-negative status was assessed by positron emission tomography-computed tomography (PET-CT) or computed tomography (CT).
|
12 weeks (84 days)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Kaplan-Meier Estimate: Progression-Free Survival (PFS)
Time Frame: up to 1 year from first dose of blinatumomab
|
PFS, calculated as the time from the date of first dose of blinatumomab until the date of diagnosis of relapse of lymphoma (by PET-CT, CT, clinical assessment or relapse biopsy, whichever was the preferred method), or date of death, whichever was earliest.
Participants who were alive and who did not have progression or new anti-tumor treatment (excluding any stem cell transplantation) were to be censored at last date of tumor assessment.
|
up to 1 year from first dose of blinatumomab
|
Kaplan-Meier Estimate: Duration of MRD-Negative Status
Time Frame: up to 1 year from first dose of blinatumomab
|
The duration of MRD-negative status, assessed only in participants who achieve MRD-negative status after blinatumomab treatment, was defined as the time when a negative MRD result was first established until documented MRD-positive re-occurrence, disease progression or, death due to any cause.
Participants without any of these events at the time of the analysis were to be censored at their last disease assessment date.
MRD-negative status was assessed by PET-CT or CT.
|
up to 1 year from first dose of blinatumomab
|
Kaplan-Meier Estimate: Overall Survival (OS)
Time Frame: up to 1 year from first dose of blinatumomab
|
OS, defined as time from the first dose of blinatumomab treatment until death due to any cause.
Participants still alive at the time of the analysis were censored at date last known to be alive.
|
up to 1 year from first dose of blinatumomab
|
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
Time Frame: From first dose of study drug through 30 days after the last dose of study drug. The treatment duration for the participant who received blinatumomab was 57 days.
|
An adverse event (AE) is defined as any untoward medical occurrence.
A serious AE is defined as an AE that is: fatal; life threatening; requires in-patient hospitalization or prolongation of existing hospitalization; results in persistent or significant disability/incapacity; a congenital anomaly/birth defect; other medically important serious event.
TEAEs are events with an onset after the administration of the first dose of blinatumomab treatment through 30 days after the end of blinatumomab treatment.
Events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE): Grade 1 (mild), Grade 2 (moderate), Grade 3 (severe), Grade 4 (life-threatening), Grade 5 (death).
|
From first dose of study drug through 30 days after the last dose of study drug. The treatment duration for the participant who received blinatumomab was 57 days.
|
Collaborators and Investigators
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Immune System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Lymphoproliferative Disorders
- Lymphatic Diseases
- Immunoproliferative Disorders
- Lymphoma, Non-Hodgkin
- Neoplastic Processes
- Lymphoma
- Lymphoma, B-Cell
- Lymphoma, Large B-Cell, Diffuse
- Neoplasm, Residual
- Antineoplastic Agents
- Blinatumomab
Other Study ID Numbers
- 20150291
- 2016-003255-30 (EUDRACT_NUMBER)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on High-risk Diffuse Large B-cell Lymphoma
-
AmgenCompletedHigh-risk Diffuse Large B-Cell LymphomaUnited States, Canada, Germany, Spain, France, United Kingdom
-
Mayo ClinicNational Cancer Institute (NCI)RecruitingRecurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent Diffuse Large B-Cell... and other conditionsUnited States
-
Australasian Leukaemia and Lymphoma GroupNot yet recruitingHigh-grade B-cell Lymphoma | DLBCL - Diffuse Large B Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | DLBCL, Nos Genetic Subtypes | High Grade B-Cell Lymphoma, Not Otherwise Specified | Follicular Large Cell Lymphoma, Relapsed | Follicular Large Cell Lymphoma
-
Northwestern UniversityNational Cancer Institute (NCI)Active, not recruitingDiffuse Large B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | High Grade B-Cell Lymphoma, Not Otherwise Specified | T-Cell/Histiocyte-Rich Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 and/or BCL6 Rearrangements | Diffuse Large B-Cell Lymphoma... and other conditionsUnited States
-
David Bond, MDRecruitingRecurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent... and other conditionsUnited States
-
National Cancer Institute (NCI)RecruitingLymphoplasmacytic Lymphoma | Ann Arbor Stage III Diffuse Large B-Cell Lymphoma | Ann Arbor Stage IV Diffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Grade 3b Follicular... and other conditionsUnited States
-
Jonsson Comprehensive Cancer CenterRecruitingProgressive Disease | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Recurrent High Grade B-Cell Lymphoma | Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular... and other conditionsUnited States
-
Lapo AlinariRecruitingRecurrent High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements | Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements | Refractory High Grade B-Cell Lymphoma With MYC... and other conditionsUnited States
-
NeoImmuneTechRecruitingRecurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Refractory High Grade B-Cell Lymphoma | Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-cell LymphomaUnited States
-
Ohio State University Comprehensive Cancer CenterRecruitingDiffuse Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Diffuse Large B-Cell Lymphoma Germinal Center B-Cell TypeUnited States
Clinical Trials on Blinatumomab
-
AmgenCompletedNon-Hodgkin's LymphomaUnited States, Australia, Italy, United Kingdom, Germany, France
-
PETHEMA FoundationTerminatedPhiladelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALLSpain
-
University of Maryland, BaltimoreActive, not recruitingMixed Phenotype Acute Leukemia (MPAL) | Measurable Residual Disease (MRD)United States
-
Gruppo Italiano Malattie EMatologiche dell'AdultoActive, not recruitingAcute Lymphoid Leukemia | Philadelphia Chromosome-Negative B-Cell PrecursorItaly
-
University of British ColumbiaAmgenTerminatedMinimal Residual Disease | B-cell Adult Acute Lymphoblastic Leukemia | Stem Cell LeukemiaCanada
-
Seoul National University HospitalAmgenRecruitingMinimal Residual Disease | Pediatric ALL, B CellKorea, Republic of
-
Assistance Publique - Hôpitaux de ParisActive, not recruitingAcute Lymphoblastic Leukemia, Adult B-CellFrance
-
A.O. Ospedale Papa Giovanni XXIIIActive, not recruitingIndolent Non-Hodgkin Lymphomas/Chronic Lymphocytic LeukemiaItaly
-
Sichuan UniversityRecruitingLeukemia, LymphoidChina
-
Sichuan UniversityNot yet recruiting